On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

SeeThruEquity Issues Update on ChineseInvestors.com (CIIX), Increases Price Target to $3.75

Less than two weeks after making a presentation at the SeeThruEquity Conference in Miami Beach, SeeThruEquity increased its price target for ChineseInvestors.com (OTCQB: CIIX) to $3.75. The previous price target for CIIX, issued in October 2016, was $2.05. SeeThruEquity delivers unbiased and unpaid for equity research for publicly traded companies with market capitalizations of less than $1 billion. The increased target price reflects the added potential from legal cannabis initiatives taken by ChineseInvestors.com. Though in the early stages of penetrating the legal cannabis market, ChineseInvestors.com has demonstrated prior success with its profitable investment in Medicine Man Technologies, generating $2.3 million in proceeds from stock sales of Medicine Man in 2016.

Traditionally, ChineseInvestors.com has delivered a broad range of products, services, and information for the Chinese speaking population, estimated at 1.2 billion people worldwide. The company provides real-time market commentary, analysis, and educational services in the Chinese language, and it offers several types of subscription-based services. Founded in 1999, the company is headquartered in Los Angeles with offices in New York City and Shanghai, China. ChineseInvestors.com also offers consultation services to private companies seeking to go public, as well as advertising and public relations services.

With a focus on value-added opportunities, the company has recently expanded into retail and online sales of cannabidiol (CBD) products. CBD is considered to have a broad range of potential medical applications, including the treatment of epilepsy. With multiple anecdotal claims of CDB efficacy in treating epilepsy, Great Britain-based GW Pharmaceuticals is seeking FDA approval to market a liquid formulation of pure plant-derived CBD. Clinical reports show CBD is devoid of the euphoric side effects associated with THC. ChineseInvestors.com markets CBD products to the Chinese people through its website, www.ChineseCBDoil.com.

Although early in market penetration, ChineseInvestors.com is among the very first to capitalize on selling CBD products to 1.2 billion Chinese people. The company has previously exhibited the ability to identify and execute upon opportunity. Given its track record, it should come as no surprise if CIIX succeeds in this new venue and, subsequently, achieves SeeThruEquity’s price target.

For more information, visit the company’s website at www.ChineseInvestors.com

About NetworkNewsWire

NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Archives

Select A Month

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217